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Abstract
Background Morbidly obese patients are at risk for non-
alcoholic fatty liver disease (NAFLD) and vitamin D deficien-
cy (VDD). Non-alcoholic steatohepatitis (NASH) is the pro-
gressive variant of NAFLD and can advance to fibrosis, cir-
rhosis, and liver cancer. We aimed to examine prevalence of
liver fibrosis and its non-invasive predictors in bariatric pa-
tients with VDD (<75 nmol/l).
Methods Baseline liver biopsy of a randomized controlled trial
was performed in 46 patients with omega loop gastric bypass.
Clinical, laboratory, and histological data were examined and
tested with univariate and multivariable analysis.
Results In total, 80 % were females, aged 42 (SD 13) years
with BMI 44 (4) kg/m2. Twenty-six percent had diabetes
mellitus (DM) and 44 % metabolic syndrome (MeS).
Seventy-two percent had NASH, 11 % simple steatosis, and
17 % normal liver. In total, 30 % demonstrated significant
fibrosis (F≥2) with 9 % of advanced (F3) and 4 % cirrhosis
(F4). Increased stages of fibrosis were primarily associated with
higher levels of HOMA2-insulin resistance (IR), procollagen
type I propeptide (P1NP), lower osteocalcin, albumin-corrected
calcium, parathyroid hormone, vitamin D, male sex, and higher
age. Other independent risk factors for advanced fibrosis were
MeS (OR=9.3 [0.99–87.5], p=0.052) and DM (OR=12.8
[1.2–137.4], p=0.035). The fibrosis FIB-4 index <10.62 and
NAFLD fibrosis score <−26.93 had a negative predictive value
of 100 and 96 %, respectively.
Conclusions Liver fibrosis is frequent in morbidly obese pa-
tients with concurrent DM and/or MeS. Increased serum levels
of IR, P1NP, lower osteocalcin, andVDD are clinically relevant
predictors of fibrosis. Consequently, we suggest that patients
with preoperative presence of these markers are at increased
risk for liver fibrosis and should be monitored closely.
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Introduction/Purpose
There is growing evidence that obesity, diabetes mellitus type
2 (DM), and the metabolic syndrome (MeS) are associated with
non-alcoholic fatty liver disease (NAFLD) [1]. NAFLD consists
of a wide spectrum ranging from relatively benign hepatic
steatosis to more severe non-alcoholic steatohepatitis (NASH)
with different stages of fibrosis ultimately progressing to cirrho-
sis and hepatocellular cancer [2]. Moreover, the association be-
tween diabetes and advanced liver disease may have important
clinical implications, particularly in morbidly obese patients, and
insulin resistance might play an important role for fibrogenesis
and carcinogenesis in the liver [3]. In the Verona Diabetes Study,
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the authors found that liver cirrhosis was the fourth leading cause
of death [4]. Furthermore, in bariatric patients, steatosis has been
reported in 85–98 %, NASH in 24–98 %, advanced fibrosis
(F≥3) in 4–16 %, and cirrhosis in 1–7 % [5]. Moreover, low
vitamin D levels, which have been associated with insulin resis-
tance (IR) and fibrogenesis [6], might also contribute to the de-
velopment ofNAFLD [7]. However, themechanisms underlying
the association of vitamin D and NAFLD are not yet fully un-
derstood and it remains unclear whether other vitamin D-related
parameters, e.g., calcium (Ca), 25-hydroxy vitamin D3
(25(OH)D3), activated 1α,25-dihydroxy vitamin D3 (1α,
25(OH)2D3), or parathyroid hormone (PTH) also have a predic-
tive value for disease progression. Of note, progressive liver
disease itself may lead to impaired vitamin D metabolism [8,
9].Moreover, morbidly obese patients with vitamin D deficiency
(VDD) may be at increased risk for liver-related mortality [10].
Therefore, the purpose of this analysis was to assess the
prevalence of liver fibrosis, to explore the role of VDD and
other additional metabolic markers as risk factors for higher
stages of liver fibrosis, and the potential of these variables to
discriminate for advanced fibrosis (F≥3) in morbidly obese
patients undergoing bariatric surgery.
Materials and Methods
From April 2014 to April 2015, consecutive patients, older
than 18 years, planned to undergo omega loop gastric bypass,
were recruited. The data for the present analysis are the result
of baseline measurements from subjects who participated in
the LOAD-study, a prospective, double-blind, randomized-
controlled vitamin D supplementation trial [11]. Alcohol in-
take was evaluated during preoperative dietary counsel-
ing on basis of the nutritional protocols and was less
than 20 or 10 g alcohol per day in men and women.
Other causes of liver disease (i.e., viral hepatitis) were
excluded by liver histology.
Informed consent was obtained from each patient included
in the study. The trial was approved by the local Ethical
Committee of the Medical University of Vienna (Ref No.:
1899/2013) and the Austrian Competent Authority (Ref.
No.: LCM-718280-0001) and conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki [12]. Furthermore,
the protocol was regis tered at cl inical t r ia ls .gov
(NCT02092376) and the European Clinical Trials Database
(EudraCT: 2013-003546-16). The study methods are in accor-
dance with the Consolidated Standards of Reporting Trials
(CONSORT) guidelines for reporting randomized trials [13].
Clinical and Laboratory Assessment
Age, sex, medical history (e.g., comorbidities), and anthropo-
metric data [weight, height, and waist circumference (WC)]
were collected [11]. After a 12-h overnight fast, venous blood
samples of each participant were obtained to determine the
liver enzymes [aspartate aminotransferase (ASAT), alanine
aminotransferase (ALAT), γ-glutamyl transpeptidase (GGT)]
[11]. Measured serum calcium concentration was corrected
for serum albumin [14]. Deficiency and insufficiency for
25(OH)D3 was defined with <50 nmol/l and 50–74.9 nmol/l,
respectively, [15] and sufficiency with >75 nmol/l. The glo-
merular filtration rates (GFR) were calculated [16]. Moreover,
we used the updated homeostatic model assessment
(HOMA2) which calculates insulin resistance (IR) [17].
Metabolic syndrome was defined according to the
International Diabetes Federation (IDF) global consensus def-
inition [18]. Additionally, we calculated non-invasive fibrosis
marker: the fibrosis FIB-4 index and NAFLD fibrosis score
(NFS) [19, 20].
Liver Biopsy and Histopathological Evaluation
Fine needle trucut biopsies were performed during the
laparoscopic omega loop gastric bypass surgery. All tis-
sues were fixed in 10 % buffered formalin and embed-
ded in paraffin. After processing, three histochemical
stains (Hematoxylin and Eosin, Chromotrope Aniline
Blue, and Prussian blue iron stains) were analyzed and
interpreted by two experienced board-certified patholo-
gists, who were unaware of the clinical data (FW, TW).
The histological scoring system NAFLD activity score
(NAS; from 0 to 8) by Kleiner et al. [21] was used to
evaluate the grade of steatosis (0–3), hepatocyte bal-
looning (0–2), lobular inflammation (0–3), and stage
of fibrosis with a four-point scale. For histological di-
agnosis of definite NASH, the diagnostic algorithm by
Bedossa et al. was used as this algorithm segregates
lesions into normal liver, simple steatosis, or NASH
and was built based on semiquantitative evaluation of
steatosis, hepatocellular ballooning, and lobular inflam-
mation in morbidly obese patients [22].
Statistical Analysis
Data are presented as mean (standard deviation) for continu-
ous variables and as percentages for categorical variables.
Proofing of normal distribution a visual inspection was used
and the Kolmogorov–Smirnov test in addition. Independent
sample t tests, the Mann–Whitney U test or Chi2 tests were
performed to compare groups. Moreover, the associations of
various factors (e.g., steatosis, fibrosis) were assessed by mul-
tiple linear regression models with backward selection of var-
iables at a p-value threshold of 0.20. All 67 variables (charac-
teristics and laboratory parameters) were tested for signifi-
cance in a simple linear regression and if significant these
variables were entered in the regression model. In addition, a
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binary logistic regression analysis was performed to identify
independent variables associated with advanced fibrosis
(F≥ 3). Adjustment for age, sex, and BMI, if appropriate,
was used to correct for effect modifiers. The statistical as-
sumptions for regression analyses were met in each case.
Moreover, the accuracy of calculated non-invasive algorithms
for detection of advanced fibrosis was assessed using receiver
operator characteristic (ROC) curves described as area under
the curve (AUC) with standard errors, the negative (NPV) and
positive predictive value (PPV). Means were compared unad-
justed without imputation of missing data. The significance
level was set at p≤0.05. The analyses were performed with
the SPSS 23.0 (IBM Corporation, NY, US)
Results
Characteristics of the Study Population
A total of 135 morbidly obese patients were recruited and
screened for study inclusion and exclusion criteria. Eighty-
five patients were excluded (68 not meeting criteria, 17 de-
clined to participate). Fifty patients were included in the study.
Out of these, 46 underwent a liver biopsy during the laparo-
scopic omega loop gastric bypass surgery (4 liver biopsies
were omitted due to logistical reasons).
Caucasian was the predominant ethnicity (90 %) followed
by African (4 %), Latin American (2 %), and other (2 %).
Table 1 Parameters (selected)
and liver histology according to
the metabolic syndrome
Total (n= 50) No MeS (n= 28) MeS (n= 22) p value
Age (years) 42 (13) 36 (13) 51 (7) < 0.001
Sum drugs (n) 6 (8) 2 (3) 10 (10) < 0.001
Weight (kg) 120.1 (13.3) 122.0 (13.1) 117.6 (13.3) 0.247
BMI (kg m−2) 43.8 (4.3) 44.5 (4.8) 42.9 (3.5) 0.190
WC (cm) 127.4 (10.6) 127.7 (11.0) 127.0 (10.3) 0.802
Corr. Ca (mmol/l) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 0.502
PTH (pg/ml) 48.7 (14.3) 52.2 (13.9) 44.3 (14.0) 0.054
25(OH)D3 (nmol/l) 39.0 (14.4) 35.9 (12.3) 43.0 (16.0) 0.081
1α,25(OH)2D3 (pg/ml) 46.9 (16.2) 49.0 (17.1) 44.0 (14.8) 0.297
GFR (ml/min/1.73 m2) 95.3 (20.6) 96.8 (22.1) 93.3 (18.9) 0.369
ASAT (U/l) 28.0 (13.8) 30.3 (16.9) 25.0 (7.6) 0.143
ALAT (U/l) 36.4 (20.8) 39.8 (24.7) 32.1 (13.9) 0.175
γ-GT (U/l) 41.3 (41.1) 30.5 (19.0) 55.1 (55.9) 0.025
Total protein (g/l) 70.1 (5.1) 70.5 (4.8) 69.6 (5.4) 0.545
Albumin (g/dl) 45.4 (5.0) 45.8 (4.9) 44.8 (5.1) 0.480
TC (mg/dl) 198.2 (46.9) 189.1 (25.0) 209.8 (63.9) 0.123
HDL (mg/dl) 47.3 (12.3) 50.2 (11.3) 43.5 (12.7) 0.050
TG (mg/dl) 155.8 (79.8) 129.9 (46.3) 188.8 (100.4) 0.008
WBC (cell/ml) 8.4 (2.1) 8.5 (2.2) 8.2 (1.9) 0.691
Platelets (cell/ml) 281.2 (64.1) 283.4 (69.9) 278.5 (57.6) 0.785
hsCRP (mg/dl) 0.9 (0.7) 0.8 (0.7) 1.0 (0.8) 0.486
Glucose (mg/dl) 108.7 (36.4) 94.4 (18.7) 127.0 (44.9) 0.001
Insulin (μU/l) 24.0 (11.9) 21.6 (10.7) 27.1 (12.9) 0.103
C-peptide (ng/ml) 4.0 (0.8–7.6) 3.8 (1.1) 4.2 (1.6) 0.285
HbA1c (rel.%) 6.0 (1.3) 5.4 (0.8) 6.7 (1.4) < 0.001
HOMA2-IR 3.1 (1.6) 2.8 (1.4) 3.7 (1.8) 0.050
Significant fibrosis (F ≥ 2) 30 % 21 % 79 % 0.001
Advanced fibrosis (F ≥ 3) 13 % 17 % 83 % 0.025
Steatosis (S ≥ 1) 83 % 60 % 40 % 0.583
NASH 72 % 58 % 42 % 0.806
Data expressed as mean and standard deviations and percentages; p< 0.05 shown in italics
BMI body mass index,WC waist circumference, Ca calcium, PTH parathyroid hormone, 25(OH)D3 25-hydroxy
vitamin D3, 1α, 25(OH)2D3 1α,25-dihydroxy vitamin D3, GFR glomerular filtration rate, ASAT aspartate amino-
transferase, ALAT alanine aminotransferase, γ-GT γ-glutamyl transferase, TC total cholesterol, HDL high density
lipoprotein, TG triglycerides, WBC white blood cells, hsCRP high sensitive c-reactive protein, HbA1c glycated
hemoglobin, HOMA2-IR homeostatic model assessment insulin resistance, NASH non-alcoholic steatohepatitis
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Twenty-six percent were diagnosed with DM, 52 % hyperten-
sion, and 48 % hypertriglyceridemia. Moreover, 44 % met the
criteria for MeS and an additional 30 % exhibited at least one
to two components of the MeS. Table 1 shows all parameters
and liver histology according to the metabolic syndrome as
well as characteristics of the study population.
Hepatic Histopathology
Steatosis (≥5 %) was present in 83 %, lobular inflammation
(≥1 foci/×200) in 80 %, and hepatocyte ballooning in 91 % of
all biopsies. Diagnosis of NASH was found in 72 %, simple
steatosis without NASH in 11 %, and normal liver morpholo-
gy in 17 %. Significant fibrosis (F≥2) was observed in 30 %
of the study population with 9% of advanced fibrosis (F3) and
4 % of cirrhosis (F4). Among patients with significant fibrosis
(F≥2), 2 % demonstrated simple steatosis without NASH and
28 % NASH. Moreover, all cirrhotic patients showed NASH.
Figure 1 shows patients with normal serum levels of liver
enzymes with NASH, F2–3, and cirrhosis (F4). Study partic-
ipants with aspartate transaminase (ASAT) levels above the
upper limit of normal (male >50 and female >35 U/l) demon-
strated significantly higher glucose metabolism-related pa-
rameters compared to those with normal levels (fasting
glucose 138.7 (39.6) vs. 104.7 (34.4)mg/dl, p=0.005; insulin
33.0 (19.0) vs. 22.8 (10.4)μU/l, p=0.048;HbA1c 6.9 (1.9) vs.
5.8 (1.1) rel.%, p=0.050; HOMA2-IR 4.5 (2.6) vs. 3.0 (1.4),
p=0.033).
Non-invasive Fibrosis Markers
Calculated non-invasive fibrosis markers are able to clearly
distinguish between F≤2 and F≥3 as significant differences
in FIB-4 with 11.4 (standard error of 4.3) vs. 17.4 (8.0)
(p = 0.007) and NFS with −29.1 (3.8) vs. −25.4 (3.3)
(p=0.028) could be observed. The ROC curves of FIB-4
and NFS (Fig. 2a, b) for predicting fibrosis stage F≥3 dem-
onstrated an AUC of 0.77 (0.09) and 0.75 (0.10). The FIB-4
<10.62 had a NPV of 100 % (sensitivity 100 %; specificity
54 %) and the NFS<−26.93 a NPVof 96% (sensitivity 83 %;
specificity 69 %).
Vitamin D Metabolites
In our population, 76% demonstrated vitamin D insufficiency
(50–75 nmol/l), and 24 % deficiency (<50 nmol/l). By using
multiple linear regression, accounting for 34% of the variance
Fig. 1 Patients with normal serum levels of liver enzymes divided by
those with NASH, significant fibrosis (F2-3), and cirrhosis (F4). Note:
ASAT aspartate aminotransferase, ALAT alanine aminotransferase, γ-GT
γ-glutamyl transferase, NASH non-alcoholic steatohepatitis, F2–F3 sig-
nificant fibrosis, F4 cirrhosis
Fig. 2 Receiver operating characteristic (ROC) curves of calculated non-invasive fibrosis markers FIB-4 index (a) and NAFLD fibrosis score (NFS) (b).
Note: NAFLD non-alcoholic fatty liver disease
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(R2=0.335), 25(OH)D3 was associated with season (summer;
β = 0.418, p = 0.002) and age (β = 0.341, p = 0.013).
Moreover, 1α,25(OH)2D3 (R
2 = 0.370) was associated with
glomerular filtration rate (GFR; β=0.523, p<0.001) and, to
a lesser extent, with waist circumference (WC; β=0.289,
p=0.020).
Risk Factors for NAFLD Severity and Fibrosis
Figure 3 shows the prevalence of histological forms of
steatosis, NAFLD, and fibrosis according to the presence of
DM in the study population with significant differences in
fibrosis. Notably, we found a statistically significant differ-
ence between non-diabetics and diabetics in the fibrosis stages
(p=0.001), but not in steatosis and NAFLD. Variables leading
to higher levels of steatosis, fibrosis, and NAS score (adjusted
for age and sex) in the study population are shown in Table 2.
Steatosis and total NAS score was primarily associated with
lower levels of mean corpuscular hemoglobin (MCH), higher
alanine transaminase (ALAT) and WC. Moreover, fibrosis
was primarily associated with higher levels of HOMA2-IR,
procollagen type I propeptide (P1NP), lower osteocalcin,
albumin-corrected calcium, PTH, male sex, lower 25(OH)D3
levels, and higher age. By using ROC curves, HOMA2-IR
and HbA1c were able to significantly predict advanced fibro-
sis (F≥3) with accuracy of 0.919 (0.048, p<0.001 (Fig. 4a))
and 0.885 (0.056, p<0.001 (Fig. 4b)). A HOMA2-IR >4.1
had a NPV of 97 % and a PPV of 55 % (sensitivity 83 %;
specificity 90 %) and HbA1c >5.8 % of 35 % (sensitivity
100%; specificity 73%) but a PPVof 100%. By using logistic
regression analysis, other independent risk factors for ad-
vanced fibrosis were DM with an odds ratio (OR) of 12.8
(95 % confidence interval (CI), 1.2–137.4), p=0.035 (adjust-
ed for age) andMeS with an OR of 9.3 (0.99–87.5), p=0.052.
Discussion
In this prospective study, we observed a high prevalence of
NASH (72 %), advanced fibrosis (13 %), and cirrhosis (4 %)
within the reported range in bariatric patients of other studies
despite a lower preoperative BMI, while the overall prevalence
of steatosis (83%)was slightly lower than previously estimated
(85–98 %) [5]. Notably, the majority had normal levels liver
transaminases with one quarter (27 and 23 %) in the upper
tertile. Bariatric patients with MeS demonstrated ninefold
higher odds for fibrosis and were older compared to those
without MeS. Diabetic subjects had an even 13-fold higher
odds ratio for advanced fibrosis and presented with higher fi-
brosis stages. Regarding vitamin D, a quarter suffered from
deficiency (<50 nmol/l) and three quarters from insufficiency
(50–75 nmol/l), which is in line with previously published data
describing a 96 % prevalence of insufficiency/deficiency
(<75 nmol/l) [23]. Overall, eight factors (higher HOMA2-IR,
P1NP, age, male sex, lower osteocalcin, corrected Ca, PTH,
and 25(OH)D3) were independently associated with biopsy-
proven liver fibrosis in our study population.
As vitamin D is hydroxylated by the liver and afterwards
converted into the active form in the kidney [24], 1α,
25(OH)2D3 was primarily associated with higher levels of
GFR in our population. Since the liver is involved in vitamin
D metabolism, it may be assumed that patients with chronic
liver disease show a high prevalence of vitamin D deficiency
[6]. In our study, lower 25(OH)D3 levels were associated with
Fig. 3 Prevalence of distinct histological forms of steatosis (a), non-
alcoholic fatty liver disease (b), and fibrosis (c) according to the presence
of diabetes mellitus in the study population. Note: DM type 2 diabetes
mellitus, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic
steatohepatitis
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higher stages of fibrosis, which is in line with previously pub-
lished studies [9, 25, 26]. As serum vitamin D correlates with
a fibrogenic state in the liver, vitamin D may be an antifibrotic
treatment option in liver fibrosis [25]. Accordingly, special
attention should be paid to vitamin D deficiency particularly
regarding fibrosis progression, which can provoke chronic
inflammation and subsequent induction of liver cell apoptosis
[27] and may have synergistic effects with insulin resistance
[7]. Moreover, the bone turnover marker P1NP might be use-
ful in predicting or monitoring liver fibrosis, respectively, as
during fibrogenesis type I collagen levels increase up to eight-
fold [28, 29]. Moreover, PTH and stages of fibrosis showed a
negative association. In our study, all patients suffered from
VDD but in only 4 patients (8 %) PTH level was increased.
The cause of normal to low PTH levels in patients with VDD
and liver disease is unclear [30]. An explanation could be
specific vitamin D-receptor gene polymorphisms which might
cause suppression of PTH secretion [30, 31].
There is rising evidence that patients with advanced and
often undetected fibrosis demonstrate increased rates of mor-
tality [32] necessitating the identification of significant indi-
cators of fibrosis in morbidly obese patients. Indeed, this anal-
ysis demonstrates that patients with impaired glucose metab-
olism parameters along with vitamin D/bone turnover markers
Table 2 Multiple linear
regression analyses of
independent variables associated
with fibrosis, steatosis, and NAS
score






ß p ß p ß p
Characteristics Age (years) 0.206 0.024
Sex (male) −0.286 0.024
WC (cm) 0.284 0.016 0.218 0.055
Vitamin D 25(OH)D3 (nmol/l) −0.255 0.006
Biochemical Corr. Ca (mmol/L) −0.298 0.001
Bone turnover P1NP (ng/ml) 0.401 <0.001
Osteocalcin (ng/ml) −0.325 0.005
PTH (pg/ml) −0.290 0.004
Insulin resistance HOMA2-IR 0.474 <0.001
Liver ALAT (U/l) 0.340 0.007 0.402 0.001
Blood count MCH (pg) −0.437 <0.001 −0.474 <0.001
p < 0.05 shown in italics
WC waist circumference, 25(OH)D3 25-hydroxy vitamin D3, Ca calcium, P1NP procollagen type I propeptides,
PTH parathyroid hormone, HOMA2-IR homeostatic model assessment insulin resistance, ALAT alanine amino-
transferase, MCH mean corpuscular hemoglobin, ß standardized beta coefficient, p value
Fig. 4 Receiver operating characteristic (ROC) curves of HOMA2-insulin resistance (a) and HbA1c (b). Note: HOMA2-IR homeostatic model
assessment insulin resistance, HbA1c glycated hemoglobin
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and/or DM or MeS, respectively, might be considered as high
risk patients. However, these indicators in this relatively small
study population require prospective validation by further
larger clinical studies. Performing a liver biopsy in all bariatric
patients might be practically not feasible and too invasive.
Therefore, non-invasive fibrosis markers with a good accura-
cy predicting advanced fibrosis could be useful to identify
patients at higher risk preoperatively [19, 20]. Including addi-
tional metabolic indicators or perhaps even transient
elastography [33] might help identifying these patients. In
clinical practice, we suggest to identify these risk factors pre-
operatively and discuss the potential implications for the
planned surgical procedure in a multidisciplinary team involv-
ing surgeons, internists (endocrinologists, hepatologists), and
nutritionists. If a patient is classified as high risk, further in-
vestigation with transient elastography eventually followed by
liver biopsy appears justified. With this approach, it is not
necessary to perform liver biopsy in all bariatric patients. It
may be useful to develop an algorithm for investigation of
patients at risk and the potential consequences for modifica-
tion of postponing the surgical procedure. Nevertheless, this
needs to be precisely assessed in a prospective study.
Emerging evidence suggests that rapid weight loss during
bariatric surgery with mobilization of potentially lipotoxic fat-
ty acids might adversely affect the liver [34]. Therefore, pa-
tients with advanced fibrosis/cirrhosis may be at increased
peri- and postoperative risk for hepatic dysfunction [35].
Another explanation might be a lack of sufficient supplemen-
tation of macro- and micronutrients [34], e.g., vitamin D.
The strengths of this study are the biopsy-proven liver dis-
ease, the well-characterized study sample, and the comprehen-
sive laboratory data. Among the limitations are the relatively
small sample size and thus limited applicability to patients
with body weight below 140 kg and vitamin D deficiency.
This population, however, might represent a significant pro-
portion of patients undergoing bariatric surgery. Moreover,
due to the inclusion criteria of VDD (<75 nmol/l) in this ran-
domized controlled trial [11], no comparison between patients
with normal vitamin D levels and those with VDD was
possible.
Conclusions
The present study shows that significant fibrosis is frequent in
vitamin D deficient, morbidly obese patients with concurrent
DM, and/or MeS. Additionally, increased levels of IR, P1NP,
lower osteocalcin, and vitamin D deficiency are associated with
increased stages of fibrosis. Based on our results, we suggest that
patients with preoperative presence of such markers and high
scores of non-invasive fibrosis markers are at high risk for liver
fibrosis. As a consequence, rigorous monitoring regarding liver
function and avoidance of macro- andmicronutrient deficiencies,
in particular calcium, vitamin D, and protein, by sufficient nutri-
tional counseling must be guaranteed in a multidisciplinary team.
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